- Home
- GAME vs BNR Comparison
GAME vs BNR Comparison
Compare GAME & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- BNR
- Stock Information
- Founded
- GAME 2011
- BNR 2014
- Country
- GAME United States
- BNR China
- Employees
- GAME N/A
- BNR N/A
- Industry
- GAME
- BNR Medical Specialities
- Sector
- GAME
- BNR Health Care
- Exchange
- GAME Nasdaq
- BNR Nasdaq
- Market Cap
- GAME 27.2M
- BNR 29.1M
- IPO Year
- GAME 2009
- BNR 2020
- Fundamental
- Price
- GAME $0.85
- BNR $2.90
- Analyst Decision
- GAME Strong Buy
- BNR
- Analyst Count
- GAME 3
- BNR 0
- Target Price
- GAME $3.67
- BNR N/A
- AVG Volume (30 Days)
- GAME 433.5K
- BNR 34.9K
- Earning Date
- GAME 05-15-2025
- BNR 06-17-2025
- Dividend Yield
- GAME N/A
- BNR N/A
- EPS Growth
- GAME N/A
- BNR N/A
- EPS
- GAME N/A
- BNR N/A
- Revenue
- GAME $99,579,536.00
- BNR $72,112,038.00
- Revenue This Year
- GAME $6.08
- BNR $136.32
- Revenue Next Year
- GAME $21.94
- BNR N/A
- P/E Ratio
- GAME N/A
- BNR N/A
- Revenue Growth
- GAME 77.06
- BNR N/A
- 52 Week Low
- GAME $0.50
- BNR $2.18
- 52 Week High
- GAME $1.43
- BNR $7.90
- Technical
- Relative Strength Index (RSI)
- GAME 58.35
- BNR 45.30
- Support Level
- GAME $0.86
- BNR $2.80
- Resistance Level
- GAME $0.92
- BNR $3.29
- Average True Range (ATR)
- GAME 0.07
- BNR 0.33
- MACD
- GAME 0.01
- BNR 0.02
- Stochastic Oscillator
- GAME 50.74
- BNR 42.89
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.